Pfizer Newsroom company blog
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics…
- Points
- 0
- HN comments
- 0
- Submissions
- 0
- Cited by
- 18 commenters
Tech Industry & BusinessScience & Space2020
Cited in comments
Linked from 19 Hacker News comments by 18 different people, from Nov 2020 to Sep 2022.
Most recent:
